studi
conduct
evalu
relationship
antimicrobi
resist
antimicrobi
use
univers
hospit
taiwan
disk
suscept
data
escherichia
coli
klebsiella
pneumonia
enterobact
cloaca
serratia
marcescen
proteu
spp
pseudomona
aeruginosa
acinetobact
spp
stenotrophomona
maltophilia
nonfer
gramneg
bacilli
caus
nosocomi
infect
evalu
data
annual
patientday
annual
consumpt
defin
daili
dose
ddd
per
patientday
extendedspectrum
cephalosporin
cefotaxim
ceftriaxon
ceftazidim
flumoxef
cefepim
cefpirom
inhibitor
combin
ticarcillinclavulan
acid
piperacillintazobactam
carbapenem
imipenem
meropenem
aminoglycosid
amikacin
gentamicin
tobramycin
fluoroquinolon
ciprofloxacin
oral
inject
oral
levofloxacin
moxifloxacin
analys
increas
trend
incid
sever
bacteria
caus
nosocomi
infect
nosocomi
bloodstream
infect
note
annual
patientday
hospit
significantli
increas
linear
regress
analysi
p
slightli
decreas
owe
sever
acut
respiratori
syndrom
epidem
taiwan
rise
cefotaximeresist
ciprofloxacinresist
e
coli
meropenemresist
p
aeruginosa
significantli
correl
increas
consumpt
extendedspectrum
cephalosporin
inhibitor
combin
carbapenem
fluoroquinolon
aminoglycosid
ciprofloxacinresist
e
coli
meropenemresist
p
aeruginosa
hospit
pearson
correl
coeffici
r
pvalu
increas
ciprofloxacinresist
k
pneumonia
meropenemresist
acinetobact
spp
significantli
associ
increas
usag
extendedspectrum
cephalosporin
four
class
antibiot
studi
hospit
demonstr
signific
chang
antimicrobi
use
may
affect
antimicrobi
resist
certain
gramneg
bacteria
hospit
antimicrobi
resist
increas
threat
hospitalis
patient
mortal
morbid
infect
greater
caus
antimicrobialresist
bacteria
among
resist
bacteria
extendedspectrum
cephalosporinresist
enterobacteriacea
carbapenemresist
pseudomona
aeruginosa
acinetobact
baumannii
ciprofloxacinresist
enterobacteriacea
nonfer
gramneg
bacilli
nfgnb
great
concern
antimicrobi
therapi
infect
due
resist
pathogen
remain
clinic
dilemma
hospitalis
patient
increas
preval
resist
pathogen
hospit
frequent
relat
high
select
pressur
antimicrobi
commonli
use
hospitalis
patient
particularli
extendedspectrum
cephalosporin
inhibitor
combin
carbapenem
fluoroquinolon
aminoglycosid
importantli
suscept
profil
nosocomi
pathogen
affect
singl
agent
also
use
multipl
agent
higher
resist
organ
antimicrobi
agent
frequent
associ
heavi
use
fewer
antimicrobi
understand
hospit
antibiogram
hospit
profil
antimicrobi
use
mandatori
solv
problem
antimicrobi
resist
hospit
report
aim
evalu
antimicrobi
usag
antimicrobi
resist
trend
promin
nosocomi
gramneg
pathogen
univers
hospit
taiwan
antimicrobialresist
pathogen
annual
resist
rate
usag
singl
agent
sever
class
agent
analys
nation
taiwan
univers
hospit
ntuh
tertiari
referr
centr
universityaffili
hospit
bed
bed
intens
care
unit
bed
haemooncolog
ward
hospit
studi
period
nosocomi
infect
control
committe
hospit
establish
prior
specif
wellestablish
antibiot
control
polic
implement
hospit
attend
physician
hospit
prescrib
nearli
antimicrobi
agent
except
liposom
amphotericin
b
voriconazol
caspofungin
linezolid
ganciclovir
without
permiss
infect
diseas
specialist
definit
nosocomi
infect
follow
nation
nosocomi
infect
surveil
guidelin
annual
incid
sever
major
gramneg
bacteria
caus
nosocomi
infect
bloodstream
respiratori
tract
urinari
tract
gastrointestin
surgic
site
skin
soft
tissu
infect
nosocomi
bloodstream
infect
express
episod
per
discharg
organ
includ
escherichia
coli
klebsiella
pneumonia
enterobact
cloaca
serraba
marcescen
proteu
spp
p
aeruginosa
acinetobact
spp
stenotrophomona
maltophilia
nfgnb
p
aeruginosa
acinetobact
spp
maltophilia
pseudomona
fluorescen
pseudomona
putida
acinetobact
junii
acinetobact
haemolyticu
acinetobact
lwoffii
burkholderia
cepacia
chryseobacterium
indologen
chryseobacterium
meningosepticum
alcaligen
spp
hereaft
nfgnb
isol
nondupl
sampl
sever
isol
speci
patient
recov
day
consid
one
isol
isol
identifi
convent
biochem
test
well
two
commerci
identif
kit
vitek
identif
card
biomerieux
hazelwood
mo
phoenix
system
becton
dickson
spark
md
necessari
data
annual
consumpt
extendedspectrum
cephalosporin
cefotaxim
ceftriaxon
ceftazidim
flumoxef
cefepim
cefpirom
inhibitor
combin
ticarcillinclavulan
acid
piperacillintazobactam
carbapenem
imipenem
meropenem
aminoglycosid
amikacin
gentamicin
tobramycin
fluoroquinolon
ciprofloxacin
oral
inject
oral
levofloxacin
moxifloxacin
obtain
pharmaci
depart
hospit
antibiot
consumpt
express
number
defin
daili
dose
ddd
patientday
determin
secular
trend
resist
major
gramneg
pathogen
caus
nosocomi
infect
ntuh
data
disk
diffus
suscept
organ
recov
retriev
annual
summari
document
calcul
resist
rate
isol
speci
ident
resist
profil
recov
patient
within
day
calcul
nondupl
isol
screen
extendedspectrum
esbl
phenotyp
among
e
coli
k
pneumonia
isol
began
escherichia
coli
k
pneumonia
isol
inhibit
zone
diamet
cefotaxim
g
disk
aztreonam
g
disk
mm
subject
esbl
confirm
method
use
follow
four
antimicrobi
disk
cefotaxim
g
cefotaximeclavulan
acid
g
disk
ceftazidim
g
disk
ceftazidimeclavulan
acid
g
disk
result
interpret
base
nation
committe
clinic
laboratori
standard
nccl
criteria
regular
qualiti
assur
perform
among
isol
process
use
follow
american
type
cultur
collect
atcc
strain
e
coli
atcc
k
pneumonia
atcc
confirm
test
esblproduc
strain
p
aeruginosa
atcc
isol
classifi
suscept
resist
includ
intermedi
categori
accord
nccl
criteria
pearson
correl
coeffici
use
determin
relationship
antibiot
consumpt
trend
resist
linear
regress
analysi
use
analys
trend
hospit
patientday
trend
rate
among
gramneg
pathogen
caus
nosocomi
infect
nosocomi
bloodstream
infect
time
trend
annual
resist
rate
antimicrobi
agent
microorgan
perform
use
durbinwatson
statist
rvalu
pvalu
consid
statist
signific
autoregress
integr
move
averag
arima
model
use
demonstr
time
seri
antimicrobi
resist
antimicrobi
use
cefotaxim
resist
e
coli
ceftazidim
resist
p
aeruginosa
annual
rate
major
gramneg
bacilli
caus
nosocomi
infect
nosocomi
bloodstream
infect
shown
fig
respect
baumannii
increas
nosocomi
bloodstream
infect
note
discharg
versu
discharg
along
increas
nosocomi
infect
discharg
versu
discharg
increas
nfgnb
caus
nosocomi
bloodstream
infect
discharg
versu
discharg
among
eight
gramneg
bacteri
speci
nfgnb
isol
trend
increas
incid
signific
r
p
among
e
coli
nfgnb
caus
nosocomi
infect
among
e
coli
k
pneumonia
serratia
spp
proteu
spp
p
aeruginosa
acinetobact
spp
caus
nosocomi
bloodstream
infect
tabl
annual
patientday
hospit
significantli
increas
linear
regress
analysi
p
slightli
decreas
owe
sever
acut
respiratori
syndrom
epidem
taiwan
fig
tabl
show
annual
consumpt
sever
commonli
use
antimicrobi
agent
fig
illustr
annual
consumpt
five
class
agent
gener
usag
individu
antimicrobi
agent
vari
year
signific
stepwis
increas
consumpt
r
p
found
piperacillintazobactam
cefepim
meropenem
ciprofloxacin
tabl
overal
rate
resist
cefotaxim
e
coli
k
pneumonia
howev
base
nccl
guidelin
esbl
confirm
test
rate
esblproduc
isol
e
coli
k
pneumonia
respect
tabl
show
trend
resist
rate
among
gramneg
pathogen
signific
increas
resist
rate
time
r
p
found
cefotaximeand
ciprofloxacinresist
e
coli
cefepimeand
ciprofloxacinresist
k
pneumonia
cefepimeand
meropenemresist
p
aeruginosa
ceftazidim
piperacillintazobactam
gentamicinand
amikacinresist
baumannii
cefepimeand
piperacillintazobactam
tabl
annual
consumpt
sever
repres
antimicrobi
agent
nation
taiwan
resist
maltophilia
significantli
increas
suscept
time
r
p
found
ceftazidim
amikacin
p
aeruginosa
tabl
relationship
rate
resist
gramneg
pathogen
caus
nosocomi
infect
annual
consumpt
correspond
antibiot
hospit
shown
tabl
signific
posit
associ
increas
resist
associ
increas
consumpt
r
p
found
cefotaximeand
ciprofloxacinresist
e
coli
cefotaximeand
gentamicinresist
marcescen
ciprofloxacinresist
p
aeruginosa
piperacillintazobactam
amikacinand
meropenemresist
baumannii
signific
neg
associ
r
p
found
cefepimeand
gentamicinresist
baumannii
rise
cefotaximeresist
e
coli
significantli
correl
increas
consumpt
extendedspectrum
cephalosporin
r
p
inhibitor
combin
r
p
carbapenem
r
p
fluoroquinolon
r
p
rise
cefotaximeresist
k
pneumonia
significantli
associ
use
extendedspectrum
cephalosporin
r
p
fluoroquinolon
r
p
increas
rate
ciprofloxacinresist
e
coli
meropenemresist
p
aeruginosa
significantli
correl
increas
consumpt
extendedspectrum
cephalosporin
r
p
r
p
respect
inhibitor
combin
r
p
r
p
respect
carbapenem
r
p
r
p
respect
fluoroquinolon
r
p
r
p
respect
decreas
use
aminoglycosid
significantli
associ
increas
incid
ciprofloxacinresist
e
coli
r
p
meropenemresist
p
aeruginosa
r
p
increas
meropenemresist
acinetobact
spp
significantli
associ
increas
usag
extendedspectrum
cephalosporin
r
p
carbapenem
r
p
four
class
antibiot
relationship
rate
ciprofloxacin
resist
k
pneumonia
p
aeruginosa
five
class
antimicrobi
signific
tabl
show
arima
transfer
function
model
estim
percentag
cefotaxim
resist
among
e
coli
isol
increas
patientday
cefotaxim
result
increas
cefotaxim
resist
rate
forecast
cefotaxim
resist
e
coli
ceftazidim
resist
p
aeruginosa
shown
fig
predict
cefotaxim
resist
percentag
e
coli
confid
interv
ci
predict
ceftazidim
resist
percentag
p
aeruginosa
ci
studi
regard
associ
antimicrobi
resist
gramneg
bacteria
caus
nosocomi
infect
antibiot
use
taiwanes
teach
hospit
increas
annual
patientday
period
disclos
three
import
point
first
incid
nosocomi
bacteraemia
due
major
gramneg
bacteria
gener
increas
time
notabl
trend
antimicrobi
usag
demonstr
sharp
increas
use
piperacillintazobactam
cefepim
ciprofloxacin
tabl
relationship
annual
consumpt
individu
antibiot
rate
key
resist
gramneg
pathogen
caus
nosocomi
infect
nation
taiwan
carbapenem
decreas
use
amikacin
sulphamethoxazoletrimethoprim
second
widespread
use
four
major
class
antimicrobi
agent
hospit
significantli
associ
increas
cefotaxim
ciprofloxacin
resist
e
coli
carbapenem
resist
p
aeruginosa
increas
use
extendedspectrum
cephalosporin
also
significantli
relat
increas
incid
cefotaxim
resist
k
pneumonia
carbapenem
resist
acinetobact
spp
increas
use
fluoroquinolon
also
significantli
associ
increas
incid
cefotaxim
resist
k
pneumonia
carbapenem
resist
p
aeruginosa
third
decreas
use
gentamicin
amikacin
recent
year
associ
increas
suscept
marcescen
gentamicin
p
aeruginosa
amikacin
howev
resist
gentamicin
amikacin
baumannii
remain
high
relationship
antimicrobi
resist
antimicrobi
usag
particular
drug
class
drug
organ
combin
partli
line
previou
studi
signific
posit
correl
increas
use
extendedspectrum
cephalosporin
particularli
ceftazidim
increas
preval
ceftazidimeresist
k
pneumonia
enterobact
spp
p
aeruginosa
describ
mani
previou
report
studi
demonstr
posit
associ
cefotaxim
use
cefotaximeresist
marcescen
howev
significantli
increas
use
cefepim
ntuh
fail
result
increas
rate
cefepim
resist
baumannii
even
exert
protect
effect
resist
r
p
use
piperacillintazobactam
demonstr
reduc
rate
ceftazidimeresist
esblproduc
k
pneumonia
howev
studi
show
significantli
posit
associ
piperacillintazobactam
use
piperacillintazobactamresist
baumannii
although
consumpt
ceftazidim
decreas
approxim
onehalf
although
piperacillintazobactam
use
increas
dramat
cefotaxim
resist
k
pneumonia
remain
high
rate
piperacillintazobactam
resist
gramneg
bacteria
remain
stabl
howev
cefotaxim
resist
enterobact
spp
ceftazidimeresist
p
aeruginosa
declin
gradual
incid
esblproduc
e
coli
k
pneumonia
avail
prior
possibl
defin
relationship
antimicrobi
usag
incid
esblproduc
isol
previou
report
demonstr
fluoroquinolon
protect
isol
thirdgener
cephalosporinresist
pathogen
recent
studi
demonstr
higher
hospitallevel
use
fluoroquinolon
associ
increas
proport
ciprofloxacin
resist
among
p
aeruginosa
isol
caus
hospitalacquir
infect
e
coli
isol
howev
macdougal
et
al
demonstr
signific
relationship
total
hospit
fluoroquinolon
use
resist
e
coli
studi
increas
use
fluoroquinolon
associ
increas
incid
cefotaximeresist
e
coli
k
pneumonia
also
correl
vari
degre
increas
ciprofloxacin
resist
among
gramneg
bacteria
except
maltophilia
isol
root
caus
rapid
emerg
dissemin
drugresist
bacteria
hospit
multifactori
includ
high
select
pressur
result
inappropri
widespread
use
antimicrobi
agent
particularli
intens
care
unit
cross
transmiss
patient
patient
owe
inconsist
applic
appropri
infect
control
measur
interhospit
transfer
resist
clonal
spread
resist
bacteria
horizont
transfer
resist
gene
commun
contribut
resist
complex
relationship
resist
use
varieti
antimicrobi
howev
increas
resist
may
drive
increas
consumpt
sever
socal
lastlin
antimicrobi
agent
studi
increas
incid
nosocomi
infect
due
multidrugresist
p
aeruginosa
baumannii
cefotaximeresist
e
coli
k
pneumonia
result
increas
use
carbapenem
increas
use
agent
significantli
associ
increas
incid
nosocomi
infect
due
carbapenemresist
baumannii
p
aeruginosa
maltophilia
nfgnb
particularli
among
patient
hospitalis
intens
care
unit
data
shown
previou
studi
demonstr
spread
pauciclon
carbapenemresist
pandrugresist
baumannii
polyclon
carbapenemresist
p
aeruginosa
intens
care
unit
ward
hospit
contribut
significantli
increas
rate
carbapenem
resist
among
isol
recent
arima
model
wide
use
investig
relationship
antibiot
use
antibiot
resist
provid
forecast
resist
base
past
antibiot
use
resist
data
owe
huge
databas
studi
model
use
analys
cefotaxim
resist
e
coli
ceftazidim
resist
p
aeruginosa
result
clearli
demonstr
trend
worsen
cefotaxim
resist
e
coli
favour
suscept
p
aeruginosa
ceftazidim
next
year
conclus
studi
hospit
demonstr
signific
chang
antimicrobi
use
might
affect
antimicrobi
resist
certain
gramneg
bacteria
hospit
chang
could
due
sever
factor
like
conjunct
one
anoth
dissemin
feedback
data
clinician
decisionmak
hospit
crucial
improv
antibiot
prescrib
implement
effect
infect
control
judici
use
antimicrobi
agent
necessari
limit
trend
